Glenmark Pharmaceuticals Limited Share Price

Equities

GLENMARK

INE935A01035

Pharmaceuticals

Market Closed - NSE India S.E. 05:13:47 26/04/2024 pm IST 5-day change 1st Jan Change
1,079 INR -0.09% Intraday chart for Glenmark Pharmaceuticals Limited +5.16% +26.39%
Sales 2024 * 121B 1.46B Sales 2025 * 140B 1.68B Capitalization 305B 3.65B
Net income 2024 * 33.36B 400M Net income 2025 * 11.13B 133M EV / Sales 2024 * 2.67 x
Net Debt 2024 * 19.84B 238M Net cash position 2025 * 3.08B 36.94M EV / Sales 2025 * 2.15 x
P/E ratio 2024 *
42.6 x
P/E ratio 2025 *
25 x
Employees 15,556
Yield 2024 *
0.21%
Yield 2025 *
0.26%
Free-Float 49.03%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.09%
1 week+5.16%
Current month+12.61%
1 month+12.76%
3 months+21.13%
6 months+44.09%
Current year+26.39%
More quotes
1 week
1 017.50
Extreme 1017.5
1 096.00
1 month
954.25
Extreme 954.25
1 096.00
Current year
771.00
Extreme 771
1 096.00
1 year
536.25
Extreme 536.25
1 096.00
3 years
348.50
Extreme 348.5
1 096.00
5 years
161.65
Extreme 161.65
1 096.00
10 years
161.65
Extreme 161.65
1 262.90
More quotes
Managers TitleAgeSince
Founder - -
Chief Executive Officer 54 12/98/12
President - -
Members of the board TitleAgeSince
Director/Board Member 59 14/20/14
Director/Board Member 56 06/99/06
Chief Executive Officer 54 12/98/12
More insiders
Date Price Change Volume
26/24/26 1,079 -0.09% 475,440
25/24/25 1,080 +0.87% 1,101,089
24/24/24 1,071 +3.52% 657,378
23/24/23 1,034 -0.47% 1,223,564
22/24/22 1,039 +1.26% 260,452

Delayed Quote NSE India S.E., April 26, 2024 at 05:13 pm IST

More quotes
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
1,079 INR
Average target price
962.8 INR
Spread / Average Target
-10.80%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. GLENMARK Stock